Balo concentric sclerosis (BCS) is a rare and striking demyelinating disease that belongs to the spectrum of multiple sclerosis (MS)-related disorders. First described by József Mátyás Baló in 1928, the condition is characterized by alternating rings of demyelinated and preserved white matter in the brain, forming a pattern likened to “onion bulbs” on magnetic resonance imaging (MRI). Although its histopathologic hallmark makes it visually distinctive, Balo concentric sclerosis presents significant diagnostic and therapeutic challenges due to its rarity, heterogeneous clinical presentation, and overlapping features with other central nervous system (CNS) demyelinating diseases.

In recent years, advances in neuroimaging, immunopathology, and molecular diagnostics have broadened our understanding of this elusive disorder. However, it remains a clinical enigma—demanding a high index of suspicion, multidisciplinary evaluation, and an individualized approach to management. This article explores the clinical features, diagnostic strategies, underlying pathophysiology, and treatment approaches for Balo concentric sclerosis, shedding light on a condition that, while rare, holds valuable insights for the broader field of neuroinflammatory disorders.

Understanding Balo Concentric Sclerosis

Definition and Historical Context

Balo concentric sclerosis is a demyelinating disease marked by concentric lamellae of alternating preserved and destroyed myelin in cerebral white matter. Initially regarded as a variant of multiple sclerosis, BCS has since been debated as a separate entity due to unique clinical, radiographic, and histological features.

The disorder is often referred to as Balo’s disease and is considered part of the atypical inflammatory demyelinating diseases (IDDs) of the CNS. Its inclusion in the MS spectrum stems from occasional co-occurrence and histological similarities with conventional MS, but its clinical course and presentation can diverge significantly.

Epidemiology and Demographics

BCS is exceedingly rare, with fewer than 300 documented cases in the literature. Most cases have been reported in Asia, particularly East and Southeast Asia, though this may reflect diagnostic biases and geographic access to advanced neuroimaging.

The condition typically affects young adults, with a mean onset age of 30 years. Both sexes are affected, though some series suggest a slight male predominance. Because of the rarity, long-term epidemiological data are lacking, and incidence rates remain speculative.

Clinical Features and Presentation

The clinical presentation of Balo concentric sclerosis varies widely, ranging from mild focal neurological deficits to rapid neurological decline resembling a space-occupying lesion. Common symptoms include:

• Motor deficits: Patients may present with progressive weakness, often in a hemiparetic distribution, reflecting involvement of corticospinal tracts. In some cases, motor symptoms can mimic a stroke or brain tumor.
• Headache and seizures: Headaches are frequently reported, often accompanied by focal or generalized seizures. These symptoms may result from inflammation and mass effect in affected brain regions.
• Cognitive and behavioral changes: Depending on lesion location, cognitive disturbances, memory impairment, and personality changes may occur, occasionally resembling frontotemporal dementia or encephalitis.
• Cranial nerve involvement: Visual disturbances, facial numbness, or diplopia may occur due to brainstem involvement in certain cases.
• Encephalopathic features: In fulminant cases, rapid deterioration in consciousness and responsiveness can occur, potentially progressing to coma.

The variability in clinical features necessitates a broad differential diagnosis during initial evaluation.

Diagnostic Challenges

Diagnosing BCS requires an integrative approach that includes clinical assessment, neuroimaging, cerebrospinal fluid (CSF) analysis, and occasionally, brain biopsy.

Neuroimaging

Magnetic resonance imaging (MRI) is the cornerstone of BCS diagnosis. The classic imaging appearance includes:

• Concentric rings of demyelination and preserved myelin: These alternating bands are best visualized on T2-weighted and fluid-attenuated inversion recovery (FLAIR) sequences, appearing as onion-like whorls.
• Gadolinium enhancement: Active lesions may show ring enhancement, indicating breakdown of the blood-brain barrier and ongoing inflammation.
• Diffusion-weighted imaging (DWI): This can demonstrate restricted diffusion in actively demyelinating areas, assisting in distinguishing active from inactive lesions.

The pathognomonic pattern on MRI is highly suggestive of BCS and can obviate the need for invasive biopsy in typical cases.

Cerebrospinal Fluid Analysis

CSF studies in BCS are nonspecific but can aid in excluding infections or malignancies. Findings may include:

• Mild pleocytosis or elevated protein levels, reflecting inflammatory activity.
• Absence or presence of oligoclonal bands (OCBs): While OCBs are common in MS, they are inconsistently found in BCS, further complicating its classification.

Brain Biopsy

In uncertain cases or when malignancy is strongly suspected, a stereotactic brain biopsy may be warranted. Histopathology reveals concentric zones of demyelination alternating with relatively preserved myelin, perivascular lymphocytic infiltration, and activated microglia.

Pathophysiology and Mechanisms

The precise pathogenesis of Balo concentric sclerosis remains poorly understood, but emerging theories point to a combination of immunological, genetic, and metabolic factors.

Immunologic Basis

Evidence supports an autoimmune etiology involving T-cell mediated inflammation and macrophage activation. The concentric pattern may result from periodic waves of demyelinating activity surrounding a central inflammatory nidus.

Oligodendrocyte Dysfunction

Some researchers hypothesize that BCS may arise from selective oligodendrocyte injury, with areas of preserved myelin representing transient recovery or resistance phases.

Hypoxia-like Tissue Injury

Recent neuropathologic analyses suggest that BCS lesions share molecular signatures with hypoxia-induced injury, including upregulation of hypoxia-inducible factor 1-alpha (HIF-1α). This has led to speculation that microvascular compromise or metabolic stress might contribute to lesion formation.

Differentiating Balo Concentric Sclerosis from Other Disorders

Balo concentric sclerosis must be distinguished from other CNS conditions that present with demyelinating lesions or ring-enhancing brain lesions. A comparison is presented in the table below:

Correct identification is crucial, as the management and prognosis differ dramatically.

Treatment Strategies

Management of Balo concentric sclerosis lacks standardized guidelines due to its rarity and variability in presentation. Treatment typically aims to reduce inflammation, manage symptoms, and prevent recurrences.

Corticosteroids

High-dose intravenous methylprednisolone is the first-line treatment for acute exacerbations. Corticosteroids reduce inflammation and edema and can lead to rapid clinical improvement in many cases.

Immunosuppressive and Immunomodulatory Agents

For patients with relapsing or progressive disease:

• Plasma exchange (PLEX): Often used in steroid-refractory cases, PLEX removes circulating autoantibodies and inflammatory mediators, potentially halting disease progression.
• Cyclophosphamide or azathioprine: These cytotoxic agents have been used in severe or relapsing cases to suppress autoimmune responses.
• Disease-modifying therapies (DMTs) for MS: Agents such as interferon beta, glatiramer acetate, or newer monoclonal antibodies may be considered, particularly when overlap with MS is suspected. However, data supporting their use in BCS specifically are limited.

Symptomatic Management

• Anticonvulsants: For patients with seizures, agents like levetiracetam or lamotrigine may be employed to maintain seizure control.
• Rehabilitation therapy: Physical and occupational therapy can support recovery in patients with motor deficits or cognitive decline.
• Psychological support: Due to the uncertain prognosis and potential for disability, mental health support plays a key role in comprehensive care.

Prognosis and Disease Course

The clinical course of Balo concentric sclerosis is unpredictable. Some patients experience monophasic illness with complete recovery, while others develop recurrent episodes or progress to chronic MS-like disease.

Prognostic factors include:

• Response to corticosteroids: A favorable response to steroids often indicates a more benign course.
• Extent and number of lesions: Patients with a single lesion and minimal enhancement generally fare better than those with multifocal disease or brainstem involvement.
• Overlap with MS: Cases that later develop typical MS lesions may follow a more relapsing or progressive pattern.

Long-term follow-up with serial imaging and clinical evaluation is essential for detecting evolution of disease and tailoring treatment.

Emerging Research and Future Directions

Recent advances in neuroimmunology and imaging have sparked interest in further characterizing Balo concentric sclerosis as a distinct demyelinating entity. Current areas of investigation include:

• Biomarker development: Identifying specific molecular markers that differentiate BCS from other demyelinating conditions could improve diagnostic accuracy.
• Imaging innovations: Ultra-high-field MRI and quantitative imaging techniques are enhancing lesion characterization and may aid in early detection.
• Pathogenetic studies: Research into metabolic and hypoxia-related injury pathways may open new therapeutic targets beyond immunosuppression.

While much remains to be discovered, these developments highlight the need for centralized registries and collaborative studies to advance clinical understanding.

Conclusion

Balo concentric sclerosis is a rare but instructive demyelinating disease that challenges clinicians with its variable presentation, unique pathology, and uncertain prognosis. Although considered a variant of multiple sclerosis, it displays distinct imaging and histological features that may warrant recognition as a separate entity.

Early identification through characteristic MRI patterns, prompt immunotherapy, and careful long-term monitoring can significantly impact patient outcomes. As research continues to uncover the molecular underpinnings of BCS, it is hoped that more precise diagnostic tools and targeted therapies will emerge—turning clinical ambiguity into clarity.

References

• Hardy, T. A., & Chataway, J. (2013). Tumefactive demyelination: An approach to diagnosis and management. Journal of Neurology, Neurosurgery & Psychiatry, 84(9), 1047–1053.
• Lucchinetti, C. F., Gavrilova, R. H., Metz, I., et al. (2008). Clinical and radiographic spectrum of pathologically confirmed Balo’s concentric sclerosis. Brain, 131(7), 1685–1695.
• Pittock, S. J., Lucchinetti, C. F., & Parisi, J. E. (2007). Balo’s concentric sclerosis: Clinical, pathologic, and radiologic spectrum. Neurology, 69(7), 691–694.
• Wang, C., & Wu, Y. (2020). Balo’s concentric sclerosis: A case report and literature review. Frontiers in Neurology, 11, 592933.
• Masaki, K. (2015). Balo’s concentric sclerosis: New insights into the pathogenesis of a rare demyelinating disease. Neurologia medico-chirurgica, 55(6), 405–412.